These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 24157055)

  • 21. Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73,913 patients.
    Reboldi G; Gentile G; Angeli F; Ambrosio G; Mancia G; Verdecchia P
    J Hypertens; 2011 Jul; 29(7):1253-69. PubMed ID: 21505352
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies.
    Law MR; Morris JK; Wald NJ
    BMJ; 2009 May; 338():b1665. PubMed ID: 19454737
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE).
    Papademetriou V; Farsang C; Elmfeldt D; Hofman A; Lithell H; Olofsson B; Skoog I; Trenkwalder P; Zanchetti A;
    J Am Coll Cardiol; 2004 Sep; 44(6):1175-80. PubMed ID: 15364316
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Benefit and harm of intensive blood pressure treatment: Derivation and validation of risk models using data from the SPRINT and ACCORD trials.
    Basu S; Sussman JB; Rigdon J; Steimle L; Denton BT; Hayward RA
    PLoS Med; 2017 Oct; 14(10):e1002410. PubMed ID: 29040268
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Retrospective analysis of real-world efficacy of angiotensin receptor blockers versus other classes of antihypertensive agents in blood pressure management.
    Petrella R; Michailidis P
    Clin Ther; 2011 Sep; 33(9):1190-203. PubMed ID: 21885126
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of time-of-day of hypertension treatment on the J-shaped relationship between blood pressure and cardiovascular risk.
    Hermida RC; Ayala DE; Mojón A; Fernández JR
    Chronobiol Int; 2013 Mar; 30(1-2):328-39. PubMed ID: 23181738
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blunted sleep-time relative blood pressure decline increases cardiovascular risk independent of blood pressure level--the "normotensive non-dipper" paradox.
    Hermida RC; Ayala DE; Mojón A; Fernández JR
    Chronobiol Int; 2013 Mar; 30(1-2):87-98. PubMed ID: 23039824
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Primary and secondary prevention of stroke by antihypertensive drug treatment.
    Wang JG; Li Y
    Expert Rev Neurother; 2004 Nov; 4(6):1023-31. PubMed ID: 15853529
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blood pressure-lowering treatment for the prevention of cardiovascular events in patients with atrial fibrillation: An individual participant data meta-analysis.
    Pinho-Gomes AC; Azevedo L; Copland E; Canoy D; Nazarzadeh M; Ramakrishnan R; Berge E; Sundström J; Kotecha D; Woodward M; Teo K; Davis BR; Chalmers J; Pepine CJ; Rahimi K;
    PLoS Med; 2021 Jun; 18(6):e1003599. PubMed ID: 34061831
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Hypertension Optimal Treatment study and the importance of lowering blood pressure.
    Hansson L
    J Hypertens Suppl; 1999 Feb; 17(1):S9-13. PubMed ID: 10340838
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study.
    Hermida RC; Ayala DE; Mojón A; Fernández JR
    Chronobiol Int; 2010 Sep; 27(8):1629-51. PubMed ID: 20854139
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Devereux RB; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):443-57. PubMed ID: 17288698
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intensive Blood Pressure Lowering in Patients With and Patients Without Type 2 Diabetes: A Pooled Analysis From Two Randomized Trials.
    Brouwer TF; Vehmeijer JT; Kalkman DN; Berger WR; van den Born BH; Peters RJ; Knops RE
    Diabetes Care; 2018 Jun; 41(6):1142-1148. PubMed ID: 29212825
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alcohol consumption and cardiovascular risk in hypertensives with left ventricular hypertrophy: the LIFE study.
    Reims HM; Kjeldsen SE; Brady WE; Dahlöf B; Devereux RB; Julius S; Beevers G; De Faire U; Fyhrquist F; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H
    J Hum Hypertens; 2004 Jun; 18(6):381-9. PubMed ID: 15103313
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of 5413 hypertensive patients: a cross-sectional study.
    Paulsen MS; Sondergaard J; Reuther L; Larsen PS; Munck AP; Larsen PV; Damsgaard J; Poulsen L; Hansen DG; Jacobsen IA; Larsen ML; Christensen HR; Christensen B; Andersen M
    Fam Pract; 2011 Dec; 28(6):599-607. PubMed ID: 21596691
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of valsartan versus amlodipine in diabetic hypertensive patients with or without previous cardiovascular disease.
    Yamashita K; Kondo T; Muramatsu T; Matsushita K; Nagahiro T; Maeda K; Shintani S; Murohara T
    Am J Cardiol; 2013 Dec; 112(11):1750-6. PubMed ID: 24035165
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the effects of amlodipine and losartan on blood pressure and diurnal variation in hypertensive stroke patients: a prospective, randomized, double-blind, comparative parallel study.
    Kwon HM; Shin JW; Lim JS; Hong YH; Lee YS; Nam H
    Clin Ther; 2013 Dec; 35(12):1975-82. PubMed ID: 24296324
    [TBL] [Abstract][Full Text] [Related]  

  • 39. On-treatment diastolic blood pressure and prognosis in systolic hypertension.
    Fagard RH; Staessen JA; Thijs L; Celis H; Bulpitt CJ; de Leeuw PW; Leonetti G; Tuomilehto J; Yodfat Y
    Arch Intern Med; 2007 Sep; 167(17):1884-91. PubMed ID: 17893310
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials.
    Thomopoulos C; Parati G; Zanchetti A
    J Hypertens; 2014 Dec; 32(12):2285-95. PubMed ID: 25255397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.